Condensed Consolidated Statements of Changes in Stockholders Equity (Unaudited) - USD ($) $ in Thousands |
Total |
Numed |
Renergen |
Public Offering |
Common Stock |
Common Stock
Numed
|
Common Stock
Renergen
|
Common Stock
Public Offering
|
Treasury Stock |
Treasury Stock
Numed
|
Treasury Stock
Renergen
|
Treasury Stock
Public Offering
|
Additional Paid-In Capital |
Additional Paid-In Capital
Numed
|
Additional Paid-In Capital
Renergen
|
Additional Paid-In Capital
Public Offering
|
Accumulated Other Comprehensive (Loss) Income |
Accumulated Other Comprehensive (Loss) Income
Numed
|
Accumulated Other Comprehensive (Loss) Income
Renergen
|
Accumulated Other Comprehensive (Loss) Income
Public Offering
|
Accumulated Deficit |
Accumulated Deficit
Numed
|
Accumulated Deficit
Renergen
|
Accumulated Deficit
Public Offering
|
Noncontrolling Interest |
Noncontrolling Interest
Numed
|
Noncontrolling Interest
Renergen
|
Noncontrolling Interest
Public Offering
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance, shares at Dec. 31, 2024 | 72,068,059 | |||||||||||||||||||||||||||
| Balance, amount at Dec. 31, 2024 | $ 51,167 | $ 721 | $ 0 | $ 105,515 | $ (2,164) | $ (56,173) | $ 3,268 | |||||||||||||||||||||
| Stock-based compensation expense | 1,890 | 0 | 0 | 1,890 | 0 | 0 | 0 | |||||||||||||||||||||
| Distribution to noncontrolling interest of VIE | (38) | 0 | 0 | 0 | 0 | 0 | (38) | |||||||||||||||||||||
| Foreign currency translation | 1,171 | 0 | 0 | 0 | 1,171 | 0 | 0 | |||||||||||||||||||||
| Net loss | (8,462) | $ 0 | 0 | 0 | 0 | (8,446) | (16) | |||||||||||||||||||||
| Balance, shares at Mar. 31, 2025 | 72,068,059 | |||||||||||||||||||||||||||
| Balance, amount at Mar. 31, 2025 | 45,728 | $ 721 | 0 | 107,405 | (993) | (64,619) | 3,214 | |||||||||||||||||||||
| Balance, shares at Dec. 31, 2024 | 72,068,059 | |||||||||||||||||||||||||||
| Balance, amount at Dec. 31, 2024 | 51,167 | $ 721 | 0 | 105,515 | (2,164) | (56,173) | 3,268 | |||||||||||||||||||||
| Distribution to noncontrolling interest of Renergen | 0 | |||||||||||||||||||||||||||
| Net loss - continuing operations | (83,619) | |||||||||||||||||||||||||||
| Net loss | (83,619) | |||||||||||||||||||||||||||
| Balance, shares at Jun. 30, 2025 | 83,905,417 | |||||||||||||||||||||||||||
| Balance, amount at Jun. 30, 2025 | 28,311 | $ 839 | 0 | 164,045 | 30 | (139,682) | 3,079 | |||||||||||||||||||||
| Balance, shares at Mar. 31, 2025 | 72,068,059 | |||||||||||||||||||||||||||
| Balance, amount at Mar. 31, 2025 | 45,728 | $ 721 | 0 | 107,405 | (993) | (64,619) | 3,214 | |||||||||||||||||||||
| Issuance of restricted common stock, shares | 2,923,783 | 7,518,797 | ||||||||||||||||||||||||||
| Issuance of restricted common stock | 0 | $ 46,761 | $ 29 | $ 75 | 0 | $ 0 | (29) | $ 46,686 | 0 | $ 0 | 0 | $ 0 | 0 | $ 0 | ||||||||||||||
| Settlement of liabilities with consultants, shares | 100,000 | |||||||||||||||||||||||||||
| Settlement of liabilities with consultants, amount | 653 | $ 1 | 0 | 652 | 0 | 0 | 0 | |||||||||||||||||||||
| Issuance Of Common Stock From Exercise Of Warrants Amount | 4,915 | $ 13 | 0 | 4,902 | 0 | 0 | 0 | |||||||||||||||||||||
| Issuance Of Common Stock From Exercise Of Warrants Shares | 1,294,778 | |||||||||||||||||||||||||||
| Stock-based compensation expense | 4,429 | $ 0 | 0 | 4,429 | 0 | 0 | 0 | |||||||||||||||||||||
| Distribution to noncontrolling interest of VIE | (41) | 0 | 0 | 0 | 0 | 0 | (41) | |||||||||||||||||||||
| Foreign currency translation | 1,023 | 0 | 0 | 0 | 1,023 | 0 | 0 | |||||||||||||||||||||
| Net loss - continuing operations | (75,157) | |||||||||||||||||||||||||||
| Net loss | (75,157) | $ 0 | 0 | 0 | 0 | (75,063) | (94) | |||||||||||||||||||||
| Balance, shares at Jun. 30, 2025 | 83,905,417 | |||||||||||||||||||||||||||
| Balance, amount at Jun. 30, 2025 | 28,311 | $ 839 | 0 | 164,045 | 30 | (139,682) | 3,079 | |||||||||||||||||||||
| Balance, shares at Dec. 31, 2025 | 111,677,771 | |||||||||||||||||||||||||||
| Balance, amount at Dec. 31, 2025 | 262,898 | $ 1,117 | $ 0 | 431,757 | 2,542 | (231,265) | 58,747 | |||||||||||||||||||||
| Issuance of common stock to acquire Renergen, shares | 14,270,000 | |||||||||||||||||||||||||||
| Issuance of common stock to acquire Renergen | $ 92,897 | $ 142 | $ 0 | $ 92,755 | $ 0 | $ 0 | $ 0 | |||||||||||||||||||||
| Forfeiture of restricted common stock, shares | (44,324) | (44,324) | ||||||||||||||||||||||||||
| Forfeiture of restricted common stock | 0 | $ 0 | $ 0 | 0 | 0 | 0 | 0 | |||||||||||||||||||||
| Stock-based compensation expense | 4,412 | 0 | 0 | 4,412 | 0 | 0 | 0 | |||||||||||||||||||||
| Deconsolidation of subsidiary | (86,783) | 0 | 0 | 0 | (9) | 0 | (86,774) | |||||||||||||||||||||
| Fair value of noncontrolling interest at acquisition | $ 597 | 7,276 | $ 0 | 0 | $ 0 | 0 | $ 0 | 0 | $ 0 | 0 | $ 0 | 0 | $ 597 | 7,276 | ||||||||||||||
| Distribution to noncontrolling interest of Renergen | (380) | 0 | 0 | 0 | 0 | (380) | 0 | |||||||||||||||||||||
| Contributions from noncontrolling interest | 26,960 | 0 | 0 | 0 | 0 | 0 | 26,960 | |||||||||||||||||||||
| Distribution to noncontrolling interest of VIE | (257) | 0 | 0 | 0 | 0 | 0 | (257) | |||||||||||||||||||||
| Foreign currency translation | (6,259) | 0 | 0 | 0 | (6,688) | 0 | 429 | |||||||||||||||||||||
| Reclassification to earnings | 0 | 0 | 0 | 0 | 1,496 | (1,496) | 0 | |||||||||||||||||||||
| Net loss - continuing operations | (26,706) | 0 | 0 | 0 | 0 | (26,463) | (243) | |||||||||||||||||||||
| Gain on deconsolidation | 20,832 | 0 | 0 | 0 | 0 | 20,832 | 0 | |||||||||||||||||||||
| Net income - discontinued operations | 3,530 | $ 0 | $ 0 | 0 | 0 | 249 | 3,281 | |||||||||||||||||||||
| Balance, shares at Mar. 31, 2026 | 44,324 | |||||||||||||||||||||||||||
| Balance, shares at Mar. 31, 2026 | 125,903,447 | |||||||||||||||||||||||||||
| Balance, amount at Mar. 31, 2026 | 299,017 | $ 1,259 | $ 0 | 528,924 | (2,659) | (238,523) | 10,016 | |||||||||||||||||||||
| Balance, shares at Dec. 31, 2025 | 111,677,771 | |||||||||||||||||||||||||||
| Balance, amount at Dec. 31, 2025 | $ 262,898 | $ 1,117 | $ 0 | 431,757 | 2,542 | (231,265) | 58,747 | |||||||||||||||||||||
| Issuance of common stock from exercise of options, shares | 62,766 | |||||||||||||||||||||||||||
| Distribution to noncontrolling interest of Renergen | $ 1,109 | |||||||||||||||||||||||||||
| Net loss - continuing operations | (60,699) | |||||||||||||||||||||||||||
| Net loss | (41,114) | |||||||||||||||||||||||||||
| Balance, shares at Jun. 30, 2026 | 131,824 | |||||||||||||||||||||||||||
| Balance, shares at Jun. 30, 2026 | 130,148,698 | |||||||||||||||||||||||||||
| Balance, amount at Jun. 30, 2026 | 274,790 | $ 1,301 | $ 1 | 533,562 | 2,666 | (272,837) | 10,097 | |||||||||||||||||||||
| Balance, shares at Mar. 31, 2026 | 125,903,447 | |||||||||||||||||||||||||||
| Balance, amount at Mar. 31, 2026 | 299,017 | $ 1,259 | 0 | 528,924 | (2,659) | (238,523) | 10,016 | |||||||||||||||||||||
| Issuance of common stock from exercise of options, shares | 62,766 | |||||||||||||||||||||||||||
| Issuance of common stock from exercise of options | 139 | $ 0 | 0 | 139 | 0 | 0 | 0 | |||||||||||||||||||||
| Issuance of restricted common stock, shares | 4,273,555 | |||||||||||||||||||||||||||
| Issuance of restricted common stock | 0 | $ 43 | $ 0 | (43) | 0 | 0 | 0 | |||||||||||||||||||||
| Forfeiture of restricted common stock, shares | (91,070) | (87,500) | ||||||||||||||||||||||||||
| Forfeiture of restricted common stock | 0 | $ (1) | $ (1) | 0 | 0 | 0 | 0 | |||||||||||||||||||||
| Stock-based compensation expense | 4,542 | 0 | 0 | 4,542 | 0 | 0 | 0 | |||||||||||||||||||||
| Distribution to noncontrolling interest of Renergen | $ (729) | $ 0 | $ 0 | $ 0 | $ 0 | $ (729) | $ 0 | |||||||||||||||||||||
| Distribution to noncontrolling interest of VIE | (215) | 0 | 0 | 0 | 0 | 0 | (215) | |||||||||||||||||||||
| Foreign currency translation | 6,029 | 0 | 0 | 0 | 5,325 | 0 | 704 | |||||||||||||||||||||
| Net loss - continuing operations | (33,993) | |||||||||||||||||||||||||||
| Net loss | (33,993) | $ 0 | $ 0 | 0 | 0 | (33,585) | (408) | |||||||||||||||||||||
| Balance, shares at Jun. 30, 2026 | 131,824 | |||||||||||||||||||||||||||
| Balance, shares at Jun. 30, 2026 | 130,148,698 | |||||||||||||||||||||||||||
| Balance, amount at Jun. 30, 2026 | $ 274,790 | $ 1,301 | $ 1 | $ 533,562 | $ 2,666 | $ (272,837) | $ 10,097 |
| X | ||||||||||
- Definition Contribution from noncontrolling interest. No definition available.
|
| X | ||||||||||
- Definition Distribution to noncontrolling interest of Renergen. No definition available.
|
| X | ||||||||||
- Definition Distribution to nonncontrolling interest of variable interest entity. No definition available.
|
| X | ||||||||||
- Definition Gain (loss) on deconsolidation. No definition available.
|
| X | ||||||||||
- Definition Income loss from discontinued operations. No definition available.
|
| X | ||||||||||
- Definition Issuance of common stock from exercise of warrants amount. No definition available.
|
| X | ||||||||||
- Definition Issuance of common stock from exercise of warrants shares. No definition available.
|
| X | ||||||||||
- Definition Settlement of liabilities with consultants amount. No definition available.
|
| X | ||||||||||
- Definition Settlement of liabilities with consultants shares. No definition available.
|
| X | ||||||||||
- Definition Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount after tax of income (loss) from continuing operations attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of increase in noncontrolling interest from a business combination. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. No definition available.
|
| X | ||||||||||
- Definition Number of shares of stock issued during the period pursuant to acquisitions. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Number of shares related to Restricted Stock Award forfeited during the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Number of share options (or share units) exercised during the current period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Value of stock issued pursuant to acquisitions during the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Value of stock related to Restricted Stock Awards forfeited during the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Value of stock issued as a result of the exercise of stock options. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of previously issued common shares repurchased by the issuing entity and held in treasury. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|